This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

Claims 1-2 (canceled)

Claim 3 (currently amended): A method for delivering a biologically active molecule into a cell comprising: 1) covalently linking a molecule to the cell surface, wherein the molecule can act as a surface receptor, 2) complexing the biologically active molecule with a ligand for the surface receptor, and 3) contacting the biologically active molecule-ligand complex with the cell surface, whereby the biologically active molecule is delivered into the cell, wherein the covalently linked molecule is biotin and the ligand is avidin or streptavidin.

Claims 4-6 (canceled)

Claim 7 (currently amended): A method for delivering a biologically active molecule into a cell comprising: 1) covalently linking a molecule to the cell surface, wherein the molecule can act as a surface receptor, 2) complexing the biologically active molecule with a ligand for the surface receptor, and 3) contacting the biologically active molecule-ligand complex with the cell surface, whereby the biologically active molecule is delivered into the cell, wherein the biologically active molecule is a nucleic acid, the ligand is PEI conjugated to avidin or streptavidin and the surface receptor is biotin, and wherein the method is not therapeutic.

Claim 8 (canceled)

Claim 9 (currently amended): A composition comprising a nucleic acid-polyethyleneimine-avidin complex, wherein the polyethyleneimine is covalently linked to avidin or streptavidin.

Claim 10 (original): The composition of claim 9, wherein the nucleic acid is selected from the group consisting of DNA and oligonucleotide.

Claims 11-16 (canceled)

Claim 17 (canceled)

Claim 18 (currently amended) A method for delivering a biologically active molecule to a cell comprising: 1) covalently linking a molecule to the cell surface, wherein the molecule can act as a surface receptor, 2) complexing the biologically active molecule with a ligand for the surface receptor, and 3) contacting the biologically active molecule-ligand complex with the cell surface, whereby the biologically active molecule is delivered to the cell, wherein the biologically active molecule is a nucleic acid, the ligand is PEI conjugated to avidin or streptavidin and the surface receptor is biotin, and wherein the method is not therapeutic.

E' cont'd